Show simple item record

dc.contributor.authorRamsay, J. R.en_US
dc.contributor.authorSuhrbier, Andreasen_US
dc.contributor.authorAylward, J.en_US
dc.contributor.authorOgbourne, S.en_US
dc.contributor.authorCozzi, S.en_US
dc.contributor.authorPoulsen, M.en_US
dc.contributor.authorBaumann, K.en_US
dc.contributor.authorWelburn, P.en_US
dc.contributor.authorRedlich, G.en_US
dc.contributor.authorParsons, Peteren_US
dc.date.accessioned2017-04-24T09:26:46Z
dc.date.available2017-04-24T09:26:46Z
dc.date.issued2011en_US
dc.date.modified2014-10-09T00:55:38Z
dc.identifier.issn00070963en_US
dc.identifier.doi10.1111/j.1365-2133.2010.10184.xen_US
dc.identifier.urihttp://hdl.handle.net/10072/44313
dc.description.abstractBackground The sap from Euphorbia peplus, commonly known as petty spurge in the U.K. or radium weed in Australia, has been used as a traditional treatment for a number of cancers. Objective To determine the effectiveness of E. peplus sap in a phase I /II clinical study for the topical treatment of basal cell carcinomas (BCC), squamous cell carcinomas (SCC) and intraepidermal carcinomas (IEC). Methods Thirty-six patients, who had refused, failed or were unsuitable for conventional treatment, were enrolled in a phase I /II clinical study. A total of 48 skin cancer lesions were treated topically with 100-300 lL of E. peplus sap once daily for 3 days. Results The complete clinical response rates at 1 month were 82% (n = 28) for BCC, 94% (n = 16) for IEC and 75% (n = 4) for SCC. After a mean follow-up of 15 months these rates were 57%, 75% and 50%, respectively. For superficial lesions < 16 mm, the response rates after follow-up were 100% for IEC (n = 10) and 78% for BCC (n = 9). Conclusions The clinical responses for these relatively unfavourable lesions (43% had failed previous treatments, 35% were situated in the head and neck region and 30% were > 2 cm in diameter), are comparable with existing nonsurgical treatments. An active ingredient of E. peplus sap has been identified as ingenol mebutate (PEP005). This clinical study affirms community experience with E. peplus sap, and supports further clinical development of PEP005 for the treatment of BCC, SCC and IEC.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_US
dc.languageEnglishen_US
dc.language.isoen_US
dc.publisherWiley-Blackwell Publishingen_US
dc.publisher.placeUnited Kingdomen_US
dc.relation.ispartofstudentpublicationNen_US
dc.relation.ispartofpagefrom633en_US
dc.relation.ispartofpageto636en_US
dc.relation.ispartofissue3en_US
dc.relation.ispartofjournalBritish Journal of Dermatologyen_US
dc.relation.ispartofvolume164en_US
dc.rights.retentionYen_US
dc.subject.fieldofresearchClinical Sciences not elsewhere classifieden_US
dc.subject.fieldofresearchcode110399en_US
dc.titleThe sap from Euphorbia peplus is effective against human nonmelanoma skin cancersen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.date.issued2011
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record